医学
受体酪氨酸激酶
激酶
癌症
酪氨酸激酶
临床试验
C-Met公司
癌症研究
受体
肿瘤科
内科学
生物
肝细胞生长因子
细胞生物学
作者
Katherine Chang,Anand B. Karnad,Shujie Zhao,James W. Freeman
出处
期刊:Oncotarget
[Impact Journals, LLC]
日期:2015-01-31
卷期号:6 (6): 3507-3518
被引量:49
标识
DOI:10.18632/oncotarget.3420
摘要
c-Met and receptor originated from nantes (RON) are structurally related transmembrane phosphotyrosine kinase receptors.c-Met and RON show increased expression or activity in a variety of tumors leading to tumor progression and may play a role in acquired resistance to therapy.Although often co-expressed, the distinct functional roles of c-Met and RON are not fully understood.c-Met and RON form both activated homodimers and heterodimers with themselves and other families of phosphotyrosine kinase receptors.Inhibitors for c-Met and RON including small molecular weigh kinase inhibitors and neutralizing antibodies are in pre-clinical investigation and clinical trials.Several of the tyrosine kinase inhibitors have activity against both c-Met and RON kinases whereas the antibodies generally are target specific.As with many targeted agents used to treat solid tumors, it is likely that c-Met/RON inhibitors will have greater benefit when used in combination with chemotherapy or other targeted agents.A careful analysis of c-Met/RON expression or activity and a better elucidation of how they influence cell signaling will be useful in predicting which tumors respond best to these inhibitors as well as determining which agents can be used with these inhibitors for combined therapy.Oncotarget 3508 www.impactjournals.com/oncotargetantibodies to the receptors or their ligands [3,[22][23][24][25][26][27][28].Although not comprehensive, this review is intended to provide a summary of the biology of c-Met and RON and the current status of drug development to these targets and the results of pre-clinical and clinical trials of these agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI